Gout Market Outlook 2025-2035: Drugs Sales, Pipeline Therapies, and Regional Outlook

Gout Market Report Overview:

Report Attribute Details

Base Year 2024

Forecast Years 2025-2035

Historical Years 2019-2024

According to the IMARC Group, the gout market size reached a value of USD 2.1 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 6.3 Billion by 2035, exhibiting a growth rate (CAGR) of 10.50% during 2025-2035.

The global gout market is expanding at a high speed, driven by an increasing number of patients and continuous development in therapeutic and diagnostic technologies. This report discusses the market dynamics of gout, its definition, current trends, and key drivers of growth in 2025. The robust growth trend of the market, despite the inherent challenges of a chronic disease, indicates both a pressing demand for effective gout therapies and the pharmaceutical industry's resolve to address it. It is interesting to note that while full information on the gout market was provided, comprehensive information on the Inflammatory Bowel Disease market was not shown in the available materials, thus the narrow scope of analysis for that industry.

Gout Market: Definition, Trends, and Drivers in 2025

Gout is a painful and common inflammatory arthritis that occurs as a consequence of hyperuricemia, a metabolic disorder characterized by an excess of uric acid in the bloodstream. The imbalance leads to the formation of sharp, needle-like uric acid crystals that accumulate in joints, soft tissue, and organs, resulting in the acute development of intense inflammation, redness, swelling, and severe pain. While the majority of individuals with elevated uric acid levels are asymptomatic, the likelihood of crystal formation and gout attacks increases with higher uric acid levels. The condition significantly impacts a patient's quality of life and has been increasing in incidence globally over the last several years.

Several interrelated factors are driving this market expansion through 2025 and beyond. A primary driver is the increasing global burden of gout, with reported cases increasing to over 53 million in 2024. This trend is robustly associated with an aging global population and the increasing incidence of lifestyle-related comorbidities, including obesity, metabolic syndrome, and diabetes. As the populations of the world age and the prevalence of these lifestyle diseases continues to increase, the number of individuals at risk of developing gout automatically goes up, offering a long-term wellspring of demand for therapeutic products.   Further, the market is powered significantly by continuous innovation in therapeutics and pipeline development.

The advent of novel urate-lowering therapies such as selective URAT1 inhibitors pozdeutinurad, ruzinurad, and SAP-001 is revolutionizing treatment. These new agents are more effective at reducing serum urate levels than some older therapies, addressing the unmet needs of patients who have an incomplete response to existing therapy. The introduction of biologic agents, particularly IL-1 antagonists, to manage acute gout flares and refractory gout is also a significant development, providing more targeted pathways to manage inflammation. This shift in drug development approach, extending beyond existing mechanisms, aims to access patient populations that have hitherto been underserved, thereby creating new market potential. Advances in diagnostic and monitoring technologies are also playing a significant role.   Development of handheld diagnostic devices that utilize holographic imaging and newer spectroscopy for detecting crystals offers easier, more accurate, and cheaper methods of gout diagnosis.

Furthermore, wearable uric acid sensors are being introduced to facilitate real-time monitoring and improve patient compliance with long-term management strategies. These technological advancements address one of the key challenges in the treatment of gout: underdiagnosis and delayed treatment, especially in the primary care setting. By making diagnosis more accessible, these technologies are expected to increase the number of diagnosed patients flowing into the treatment pathway, which will directly fuel the therapeutics market.

Request for a Sample Copy of this Report: https://www.imarcgroup.com/gout-market/requestsample

This report also provides a detailed analysis of the current gout marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape With Key Players:

The competitive landscape of the gout market has been studied in the report with the detailed profiles of the key players operating in the market.

• Horizon Therapeutics plc
• Almatica
• Takeda
• Teijin Pharma
• Fuji Yakuhin/Mochida Pharmaceutical
• Arthrosi Therapeutics
• Dyve Biosciences
• Selecta Biosciences
• Shanton Pharma
• LG Chem

Countries Covered:

United States

Germany

France

United Kingdom

Italy

Spain

Japan

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

Company Name: IMARC Group

Email: [email protected]

Phone: +1-201-971-6302

Address: 134 N 4th St

City: Brooklyn

State: NY

Country: United States

Website: https://www.imarcgroup.com/